<?xml version="1.0" encoding="UTF-8"?>
<p>
 <xref ref-type="fig" rid="molecules-26-00137-f005">Figure 5</xref> shows that administration of CTN (2, 5, 10, 15, 30, and 50 mg/kg body weight) has significantly (
 <italic>p</italic> &lt; 0.05, 
 <italic>p</italic> &lt; 0.00 = 1, 
 <italic>p</italic> &lt; 0.001) reduced MDA level in STZ-induced diabetic rats. The high dose of CTN (50 mg/kg) was more effective as compare to low doses (10 mg/kg and below). CTN treated groups exhibited reduction in lipid peroxidation, observed through significant decrease of MDA level estimated in liver (
 <xref ref-type="fig" rid="molecules-26-00137-f005">Figure 5</xref>B) and kidney (
 <xref ref-type="fig" rid="molecules-26-00137-f005">Figure 5</xref>E) tissue homogenates in comparison to the diabetic control group. Furthermore, a significant increase in the concentration of reduced GSH estimated in liver (
 <xref ref-type="fig" rid="molecules-26-00137-f005">Figure 5</xref>C) and kidney (
 <xref ref-type="fig" rid="molecules-26-00137-f005">Figure 5</xref>F) tissue homogenates of the CTN treated groups in comparison to diabetic control group was also observed.
</p>
